Lebrun C, Ghetau G, Bourg V, Chanalet S, Dumas S, Chatel M
Service de Neurologie, Hôpital Pasteur, Nice, France.
Rev Neurol (Paris). 2003 Jul;159(6-7 Pt 1):648-51.
Intravenous immunoglobulins are used in the treatment of different autoimmune diseases. Recent trials suggest their efficacy in relapsing remitting multiple sclerosis. We report the results of an efficacy and safety trial using monthly intravenous injections of immunoglobulins for patients with secondary progressive multiple sclerosis. Eighteen patients in clinical progression, who have been previously treated with immunomodulatory or immunosuppressive drugs, were given monthly intravenous immunoglobulin infusions (0.4 g/kg/d for 5 days). At the beginning, the mean EDSS score was 6.77. At the end of the study, an improvement of EDSS was noted in 61.1 p. cent of patients, with less than 1 and 0.75 for secondary and primary progressive diseases respectively. No worsening was reported. Surprisingly, some patients had partial improvement of neurological functions which were considered as sequelae. Indications for intravenous immunoglobulins in the treatment of the multiple sclerosis need to be evaluated.
静脉注射免疫球蛋白用于治疗不同的自身免疫性疾病。最近的试验表明其在复发缓解型多发性硬化症中有疗效。我们报告了一项针对继发进展型多发性硬化症患者每月静脉注射免疫球蛋白的疗效和安全性试验结果。18例处于临床进展期、先前接受过免疫调节或免疫抑制药物治疗的患者，每月接受静脉注射免疫球蛋白输注（0.4 g/kg/d，共5天）。开始时，平均扩展残疾状态量表（EDSS）评分为6.77。研究结束时，61.1%的患者EDSS有所改善，继发进展型疾病和原发进展型疾病分别改善不到1分和0.75分。未报告病情恶化情况。令人惊讶的是，一些患者被视为后遗症的神经功能有部分改善。静脉注射免疫球蛋白在多发性硬化症治疗中的适应证需要评估。
